Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of evolocumab versus LDL-apheresis in familial hypercholesterolemia
2016-002983-16Phase 3Active
- Sponsor
- SERVICIO DE NEFROLOGIA
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of evolocumab in familial hypercholesterolemia (FH) (3 arms), sponsored by SERVICIO DE NEFROLOGIA. Primary endpoint: LDL-cholesterol reduction. Started Nov 2016; status: active.
02
Drugs
evolocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2016-002983-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002983-16.